Lung Cancer Surgery after Neoadjuvant Immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Thoracic Surgery

Background:

• Recurrences are common in early-stage lung cancer even after surgical removal.
• Neoadjuvant immunotherapy is being explored to target micrometastasis before surgery.
• This approach may improve survival outcomes for lung cancer patients.

Purpose of the Study:

• To evaluate the potential of neoadjuvant immunotherapy in reducing lung cancer recurrence.
• To assess if neoadjuvant immunotherapy can improve disease-free and overall survival rates.
• To determine the safety and efficacy of neoadjuvant immunotherapy combined with other treatments.

Main Methods:

• Review of early trials investigating neoadjuvant immunotherapy in lung cancer.
• Analysis of pathologic response rates to neoadjuvant therapy.
• Assessment of surgical safety following neoadjuvant immunotherapy and chemo-(radio)therapy.

Main Results:

• Early trials indicate encouraging pathologic response rates to neoadjuvant therapy.
• Surgery is demonstrated to be safe after neoadjuvant immunotherapy regimens.
• Current data suggests potential benefits, but definitive survival data is pending.

Conclusions:

• Neoadjuvant immunotherapy is a promising strategy for early-stage lung cancer.
• Further phase III studies are crucial to confirm survival benefits.
• Combining immunotherapy with surgery and other therapies warrants continued investigation.